Episode Details

Solventum Corporation (SOLV) Q2 2026 — Q2 2026 (quarter ended June 30, 2026): sales $2,209M, +2.2% reported and +9.5% organic, ~2.6% ahead of a $2,154M estimate. Adjusted diluted EPS $2.55 vs a $1.90 bar - a 34% BEAT. GAAP diluted EPS $0.53. Adjusted operating margin 28.4% vs 21.9%. Free cash flow $144M in the quarter but MINUS $129M for the first half. FY26 guidance RAISED to $7.10-$7.20 adjusted EPS from a $6.40-$6.60 range, organic +2.5-3.0%, free cash flow $200-300M. Intent to separate Health Information Systems announced the same afternoon. Stock -5.16% to $82.96. Solventum beat by 34%, raised full-year guidance on sales, earnings AND cash, and announced its intent to separate Health Information Systems - all on the same afternoon. The stock opened at $89.27, printed a 52-week high of $90.00, and closed at $82.96, down 5.2%. This episode is about why. The company names every driver of the outperformance itself, and none of them repeat: gross margin "driven by IEEPA tariff refund", organic growth "including the expected benefit of advance orders placed ahead of ERP cutovers", and cash flow helped by "timing of tax payments and insurance proceeds". Then the arithmetic: the full-year EPS guide moved from a $6.60 high end to a $7.15 midpoint, a raise of 55 cents, while the June quarter alone beat by 65 cents - so the annual raise is a dime SMALLER than the quarterly beat. Implied second-half organic growth is about zero against +5.8% in the first half. Days sales outstanding went from 47.1 to 54.0 days. And in the half-year everyone spent calling this a deleveraging story, net debt rose $519M. We still think the shares are worth more than the tape - fair value ~$95 - but a 34% beat this borrowed does not earn a Buy. THE CALL: HOLD (3/5, A CHEAP ASSET, A BORROWED QUARTER, AND NOT ENOUGH MARGIN OF SAFETY YET) — base-case value ~$95.0 vs ~$82.96 today. KEY METRICS: - CALL: HOLD 3/5, fair value ~$95 vs the $82.96 close (+15%). Street: 11 analysts, Buy, $91.22 avg target (+10%). We AGREE on the number and DIFFER on the word. - Sales $2,209M +2.2% reported, +9.5% organic. Adjusted EPS $2.55 vs $1.90 (+34%). GAAP EPS $0.53. Adjusted op margin 28.4% vs 21.9%. H1 FCF MINUS $129M. - FY26 raise was +$0.55 but the quarter beat by $0.65. Implied H2 organic ~0%. DSO 47.1 to 54.0 days. Net debt +$519M in six months. HIS separation announced. What to watch: UP: a named structure and a price for the Health Information Systems separation rather than an intent; two consecutive quarters where free cash flow actually matches adjusted earnings; net debt that genuinely falls; or days sales outstanding back under 50. BEAR: negative organic growth in the September quarter; DSO above 54 days again; a cut to the $200-300M free cash flow guide; another print where the annual raise is smaller than the quarterly beat; or a second year of nine-figure litigation charges. Next print is early November. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.